| |
|
|
|
|
|
|
|||
|
Blood, 1 June 2007, Vol. 109, No. 11, pp. 4865-4876. Prepublished online as a Blood First Edition Paper on February 6, 2007; DOI 10.1182/blood-2006-09-045245.
IMMUNOBIOLOGY Adoptive transfer of tumor-primed, in vitro–activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response1 Center for Surgery Research, The Cleveland Clinic Foundation, Cleveland, OH; 2 Center for Translational Medicine in Women's Health, Tumor Vaccine Group, University of Washington, Seattle, WA
The importance of CD4+ Th1 cells during the effector phase of the antitumor response has been overshadowed by emphasis on CD8+ cytotoxic T lymphocytes (CTLs). To determine their respective functions, we purified antigen-primed T cells from tumor-draining lymph nodes and separately activated CD4+ and CD8+ subsets in vitro. Adoptive transfer of CD4+ T effector cells (TEs) combined with CD8+ TEs provided synergistic therapy for mice bearing subcutaneous, intracranial, or advanced pulmonary metastases. CD4+ TEs augmented IFN-
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2007 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||